These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15554782)

  • 1. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.
    Pallanti S; Hollander E; Goodman WK
    J Clin Psychiatry; 2004; 65 Suppl 14():6-10. PubMed ID: 15554782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for obsessive-compulsive disorder.
    Dougherty DD; Rauch SL; Jenike MA
    J Clin Psychol; 2004 Nov; 60(11):1195-202. PubMed ID: 15389617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
    Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
    CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
    Pallanti S; Quercioli L; Koran LM
    J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategies for obsessive-compulsive disorder.
    Marazziti D; Consoli G
    Expert Opin Pharmacother; 2010 Feb; 11(3):331-43. PubMed ID: 20102301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
    Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
    J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of obsessive-compulsive disorder and related disorders.
    Dell'Osso B; Altamura AC; Mundo E; Marazziti D; Hollander E
    Int J Clin Pract; 2007 Jan; 61(1):98-104. PubMed ID: 17229184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.
    Shanahan NA; Velez LP; Masten VL; Dulawa SC
    Biol Psychiatry; 2011 Dec; 70(11):1039-48. PubMed ID: 21920503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic therapy of obsessive compulsive disorder.
    DeVeaugh-Geiss J
    Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
    Fontenelle LF; Mendlowicz MV; Miguel EC; Versiani M
    World J Biol Psychiatry; 2005; 6(1):57-9. PubMed ID: 16097406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials.
    Romanelli RJ; Wu FM; Gamba R; Mojtabai R; Segal JB
    Depress Anxiety; 2014 Aug; 31(8):641-52. PubMed ID: 24390912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.